One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.

Indian J Ophthalmol · 2021 · PMC7933844 · PMID 33463593

Europe PMC DOI

hedged sentence

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

showed a trendP = 0.091so close (0.05 < p ≤ 0.1)

Despite the individual-level improvements, COST only showed a trend for improvement ( P = 0.091) at follow-up.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.